Sirona Biochem Corp. has entered an agreement with Wanbang Biopharmaceuticals, providing Wanbang an exclusive license to develop and commercialize its anti-diabetic SGLT2 inhibitor in the People’s Republic of China. Sirona will receive upfront and milestone payments of as much as $9.5 million, as well as royalties on sales.   Wanbang will be responsible for all funding, clinical development, regulatory requirements, manufacturing, sales and marketing of the SGLT2 inhibitor in China, and wi...